Results 11 to 20 of about 48,562 (198)

Janus kinase inhibitors: between prescription authorization and reimbursability [PDF]

Reumatismo, 2023
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli, F. Conti, R. Caporali, F. Iannone, F. Cacciapaglia, on behalf of the Steering Committee of the Italian Society of Rheumatology   +5 more
doaj   +4 more sources

Janus kinase inhibitors: jackpot or potluck?

Oncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat, Shripad Brahmanand Pande   +1 more
doaj   +2 more sources

Janus kinase inhibitors in the treatment of psoriatic arthritis

Современная ревматология, 2022
The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA ...
E. Yu. Loginova, T. V. Korotaeva
doaj   +3 more sources

Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

Acta Dermato-Venereologica
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis.
Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen   +4 more
doaj   +2 more sources

Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis [PDF]

Hospital Pharmacy, 2017
Rheumatoid arthritis (RA) is a disease where the immune system attacks the linings of the joints, resulting in joint pain, stiffness, swelling, and destruction. Although many products are available for the treatment of RA, limitations such as adverse reactions and tolerance greatly affect adherence.
Senir, Turan, Scot, Walker
openaire   +3 more sources

Effectiveness of  Janus kinase  inhibitors in  rheumatoid  arthritis:  systematic review  and  meta-analysis

Качественная клиническая практика
Aim.  To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods.
A. E. Cheberda, D. Yu. Belousov
doaj   +3 more sources

A literature review of the Janus kinase inhibitors used in the treatment of auto-immune dermatological conditions [PDF]

, 2022
© 2022 The Authors. Published by Archives of Pharmacy Practice. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.51847 ...
Morrissey, Hana, Sharara, Zinah, Ball, Patrick A., Al Abadie, Mohammed   +3 more
core   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Intraocular infections following biologicals and Janus Kinase inhibitors [PDF]

Indian Journal of Ophthalmology
Parthopratim Dutta Majumder, Rakshita Deepak Kene   +1 more
doaj   +2 more sources

Janus kinase inhibitors for the therapy of atopic dermatitis [PDF]

Allergologie select, 2021
The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals.
Traidl, Stephan, Freimooser, Sina, Werfel, Thomas   +2 more
openaire   +2 more sources